Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020)
Celldex Therapeutics' (CLDX) quarterly Long-Term Deferred Tax came in at $297.3 million in Q4 2020, up 324.52% year-on-year from $70.0 million in Q1 2020, and up 324.52% quarter-over-quarter from $70.0 million in Q4 2019.
Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Celldex Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $297.3 million for Q4 2020.
- On a quarterly basis, Long-Term Deferred Tax rose 324.52% year-over-year to $297.3 million in Q4 2020; TTM through Dec 2020 was $297.3 million, a 324.52% increase from a year earlier, with the FY2020 full-year figure at $297.3 million, up 324.52% from the prior year.
- Long-Term Deferred Tax climbed to $297.3 million in Q4 2020 per CLDX's latest filing, from $70.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $297.3 million in Q4 2020 and bottomed at $70.0 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 297.34 Mn |
| Dec 31, 2019 | 70.04 Mn |